Multiplex analysis of ovarian cancer patients using glycan microarray

cancer diagnostics and novel therapies. Glycan microarrays are effective methods for analyzing glycans and antiglycan antibodies, which are immobilized arrays of oligo- or poly-saccharides on different substrates, making them a promising class of oncological biomarkers. Blood serum samples from patients (n = 203) with ovarian cancer (OvaCan) and healthy volunteers were analyzed using a glycan microarray containing 63 immobilized glycans to determine changes in anti-glycan IgG and IgM antibody profiles in OvaCan. Levels of anti-glycan IgG and IgM antibodies in OvaCan statistically differed from levels in healthy donors: the most prominent statistically significant difference for anti-glycan IgG antibodies was found for 6-O-su-Lec (AUC = 0.657, Se = 48.0 %, and Sp = 73.3 %). The AUC values for certain glycans investigated in diagnosing OvaCan indicated a fingerprint consisting of IgM antibodies to specific glycans, and the most specific anti-glycan IgM antibodies were Ley (AUC = 0.625, Se = 98.0 % and Sp = 45.0 %). The potential of these serological biomarkers to distinguish between OvaCan and other malignancies is still an unresolved issue that requires more large-scale studies to confirm and validate the use of these biomarkers in the diagnosis of different types of cancer.